Harrow reiterates 2026 revenue guidance of $350 mln to $365 mln
Company maintains 2026 adjusted EBITDA forecast of $80 mln to $100 mln
TYRVAYA acquisition expected to contribute modestly to 2026 revenue
Overview
Ophthalmic drug maker's Q2 revenue rose 11% yr/yr, slightly beating analyst expectations
Company posted net loss per share of $0.46, down from profit last year
Result Drivers
Product demand - Co said strong demand for VEVYE, IHEEZO, and TRIESENCE drove Q2 revenue growth
Expanded coverage - VEVYE gained expanded formulary coverage with a top-three national commercial pharmacy benefit manager, effective August 1, supporting further market share growth
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell". The average consensus recommendation for the pharmaceuticals peer group is "buy". Wall Street's median 12-month price target for Harrow, Inc. is $60.00, about 48.4% above its August 7 closing price of $40.44. The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 34 three months ago.
HROW•
